Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Correction to: npj Breast Cancer (2022) 8:98; 10.1038/s41523-022-00467-1, published online 29 August 2022

The article includes two typographical errors, on pages 5 and 6. On page 5, in the sentence beginning with “Dose interruptions…”, and on page 6, in the sentence beginning with “A higher frequency…”, the order of the percentage of patients in the SG and TPC arms who discontinued treatment due to adverse events in the ASCENT trial has been written backwards. Therefore, on page 5, values “26% and 22%, respectively” have been corrected to “22% and 26%, respectively”. Similarly, on page 6, values “(26% vs. 22%, respectively)” have been corrected to “(22% vs. 26%, respectively)”.